OUI

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 10, 2023
Infection, EASL, Interferon gamma, PSA, Prostate cancer, Clinical trial, American depositary receipt, Cancer, Woman, Research, Autoimmunity, AstraZeneca, Hepatitis B, Public expenditure, Arbutus, Retirement, Investigational New Drug, ELISpot, Data, Patient, Laboratory, Immune system, Non-carious cervical lesions, HPV, Depreciation, European Association for the Study of the Liver, Vaccitech, HBV, Oxford University Innovation, IND, Disease, Conference, Safety, OUI, Nivolumab, Vaccine, Pharmaceutical industry, Clothing, Liver, HBsAg

Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.

Key Points: 
  • Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
  • The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
  • Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
  • Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Friday, May 12, 2023
Vaccine, Infection, Antigen, Prostate-specific antigen, EASL, PSA, Cancer, Woman, CHB, Hepatitis B, Research, Autoimmunity, AASLD, AstraZeneca, Șaeș, Public expenditure, Congress, Arbutus, HBsAg, Retirement, CD8, Patient, Data, Laboratory, Non-carious cervical lesions, HPV, Depreciation, Poster, European Association for the Study of the Liver, CD4, Vaccitech, IND, Oxford University Innovation, HBV, Conference, Hepatitis, Safety, OUI, Disease, Pharmaceutical industry, E5, Liver, E4, E7, E2, E6

In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.

Key Points: 
  • In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.
  • In April 2023, we announced the planned retirement of Chris Ellis, Chief Operating Officer, effective October 31, 2023.
  • Cash position: As of March 31, 2023, cash was $191.3 million, compared to $194.4 million as of December 31, 2022.
  • Revenues: Revenue were $0.5 million in the first quarter of 2023 compared to $15.0 million in the comparable period of the previous year.

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 10, 2022
AstraZeneca, Private Securities Litigation Reform Act, IV, IND, Nivolumab, Vaccine, U.S. Securities and Exchange Commission, ChAdOx1, MVA, Tumor microenvironment, Research, AASLD, HPV, G&A, Șaeș, SEC, Annual report, Degenerative disease, University, Vaccitech, Company, Vaccination, Cancer, Asian Liver Center, CHB, Clinical trial, OUI, Patient, Immune system, Autoimmunity, Ulsan College, Drug discovery, Security (finance), Insurance, COVID-19, Pharmaceutical industry, Food delivery, HBsAg, Gastroenterology, Cell

An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.

Key Points: 
  • An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.
  • On September 20, 2022, we announced the promotion of Gemma Brown to Chief Financial Officer.
  • Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Vaccitech to Present at Upcoming November Investors Conferences

Retrieved on: 
Wednesday, November 9, 2022
ChAdOx1, Oxford University Innovation, AstraZeneca, OUI, University, Immune system, Autoimmunity, Company, Cancer, MVA, COVID-19, Vaccine, Vaccitech

Vaccitech will also participate in 1x1 investor meetings at the conferences.

Key Points: 
  • Vaccitech will also participate in 1x1 investor meetings at the conferences.
  • Meetings can be booked directly with the Company or with the relevant bank representatives.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Retrieved on: 
Wednesday, November 2, 2022
Liver, ChAdOx1, University, Antigen, Liver disease, Vaccitech, Cancer, Oxford University Innovation, COVID-19, Autoimmunity, Immunotherapy, HBV, Immune system, Safety, Nivolumab, MVA, OUI, AstraZeneca, AASLD, Vaccine, D.C

Study of Liver Disease (AASLD) - The Liver Meeting, Washington, D.C.

Key Points: 
  • Study of Liver Disease (AASLD) - The Liver Meeting, Washington, D.C.
    VTP-300 is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx) and boosted with a pox virus (MVA).
  • Both vectors have been modified to improve safety, enhance the immune response they induce and include HBV specific antigens including core, polymerase and surface antigen.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

OUI Inc., the Japanese Startup of a Smartphone-based Ophthalmic Diagnostic Medical Device, Wins First Prize at AEA2022 Innovation Awards

Retrieved on: 
Tuesday, November 1, 2022
Software, Optical, Hardware, Health, Medical Devices, Technology, Apps, Applications, Mobile, Wireless, IOT, Severe cognitive impairment, DX, Life, Population, Mentorship, Health, SEC, Time, Work, AEA, Ammonia, Technology, OUI, Patient, Multimedia, Smartphone, Social Problems, Solution, Diagnosis, Renewable energy, Medicine, Medical device

Among the competing participants, Japans OUI Inc., which develops the Smart Eye Camera (SEC), a smartphone-based medical device that enables ophthalmic diagnosis anytime, anywhere, and by anyone, was chosen as the winner.

Key Points: 
  • Among the competing participants, Japans OUI Inc., which develops the Smart Eye Camera (SEC), a smartphone-based medical device that enables ophthalmic diagnosis anytime, anywhere, and by anyone, was chosen as the winner.
  • View the full release here: https://www.businesswire.com/news/home/20221031005324/en/
    AEA is a global innovation award for emerging Asian entrepreneurs and startups that are utilizing advanced technology to offer solutions to social issues.
  • Among the four participants of the session, SocialTech Japan (Japan), a provider of affordable medical services for achieving universal health coverage, won first prize.
  • For a list of startup entrants and their businesses, visit https://aea.events/e/startup-entrants/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005324/en/

Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients

Retrieved on: 
Monday, October 31, 2022
U.S. Securities and Exchange Commission, Safety, Queen Mary Hospital (Hong Kong), University, Annual report, HBV, University of Hong Kong, ChAdOx1, Private Securities Litigation Reform Act, Patient, OUI, SEC, Cancer, Oxford University Innovation, Immune system, Company, Security (finance), GLOBE, NASDAQ, Population, Autoimmunity, Vaccine, COVID-19, Queen, AstraZeneca, MVA, Hospital, HBsAg, Pharmaceutical industry, Vaccitech

HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.

Key Points: 
  • HBV003 is a Phase 2b clinical trial designed to further evaluate the safety and efficacy of VTP-300 when combined with a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection.
  • VTP-300 includes Vaccitechs prime-boost platform, which utilizes 2 nonreplicating viral vectors, ChAdOx1 and MVA.
  • Each viral vector encodes HBV antigens to elicit an immune response against HBV.
  • We have been very encouraged by data emerging from our open-label HBV002 study, which shows that VTP-300 induced significant and sustained HBsAg declines in some patients with chronic HBV.

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

Retrieved on: 
Thursday, October 27, 2022
IND, TLR, SEC, Company, University, Security (finance), U.S. Securities and Exchange Commission, TME, NASDAQ, Private Securities Litigation Reform Act, Publication, Cancer, Disease, Senior, Vaccine, Tumor microenvironment, MVA, Papilloma, Annual report, Oxford University Innovation, Nanoparticle, Drug discovery, Immune system, IV, HPV, Research, COVID-19, GLOBE, Autoimmunity, ChAdOx1, NIH, Jamil Khir Baharom, OUI, Monocyte, Macrophage, AstraZeneca, Cell, Vaccitech

OXFORD, United Kingdom, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.” The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.

Key Points: 
  • The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.
  • The research evaluated SNAPvax co-delivering tumor antigens and a powerful Toll-like receptor (TLR)-7/8 adjuvant by two different routes (IV or subcutaneous) in tumor-bearing mice.
  • The aforementioned research was first published online in Cell and can be accessed at the link in the citation below.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Retrieved on: 
Monday, October 3, 2022
MVA, AstraZeneca, University, Cancer, Immune system, OUI, Oxford University Innovation, Autoimmunity, ChAdOx1, COVID-19, Vaccine, Vaccitech

The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).

Key Points: 
  • The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).
  • The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Le Macaron French Pastries® Celebrates with Franchise Partners At "Together Towards Tomorrow" Summit in Orlando

Retrieved on: 
Tuesday, September 27, 2022
Le Macaron, OUI, Food, Peanut butter, Champagne, Growth, MI, Friends, CA, Jelly, Entrepreneurship, Restaurant, Nightclub, Celebration

SARASOTA, Fla., Sept. 27, 2022 /PRNewswire/ -- Le Macaron French Pastries, the #1 macaron franchise brand in the United States, celebrated a year of unprecedented growth, innovation, and success with its franchisees from throughout the country. Sixty-five attendees gathered in Orlando for the company's annual event with the theme "Together Towards Tomorrow," which included presentations, workshops, and discussions about how the brand's 64 locations will continue to thrive in the future.

Key Points: 
  • "Le Macaron has so much to be grateful for as we continue to grow and capitalize on our success as the #1 macaron franchise brand," she said.
  • In addition, Le Macaron introduced a new Peanut Butter and Jelly macaron and a seasonal Champagne flavored macaron.
  • Founded in 2009 by Rosalie Guillem and her daughter Audrey, Le Macaron French Pastries is an elegant French patisserie that offers guests the finest, authentic French macarons and pastries.
  • Le Macaron French Pastries is ranked on Inc. 5,000 2016, #17 on the 2019 Top Emerging Franchise List as well as ranking on the Top 100 Food and Beverage category by Entrepreneur and holds a No.